{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:49:01Z","timestamp":1781732941685,"version":"3.54.5"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The pharmacokinetic characteristics and tissue distribution of a novel water-soluble, nontoxic amphotericin B-arabinogalactan (AMB-AG) conjugate exhibited distinct differences from those of micellar and liposomal amphotericin B formulations. These differences included extended persistence of drug in the body and its accumulation in the lungs; thus, the AMB-AG conjugate was highly effective in treating systemic murine aspergillosis.<\/jats:p>","DOI":"10.1128\/aac.48.9.3606-3609.2004","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T19:12:57Z","timestamp":1093374777000},"page":"3606-3609","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Distribution of Amphotericin B-Arabinogalactan Conjugate in Mouse Tissue and Its Therapeutic Efficacy against Murine Aspergillosis"],"prefix":"10.1128","volume":"48","author":[{"given":"Rama","family":"Falk","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Pharmaceutics, The Hebrew University of Jerusalem-School of Pharmacy, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J.","family":"Domb","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhack","family":"Polacheck","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.21"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","volume":"3","year":"1993","unstructured":"Adler-Moore, J. P., and R. T. Proffitt. 1993. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of AmB. J. Liposome Res.3:429-450.","journal-title":"J. Liposome Res."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.1966.03100050079024","volume":"195","year":"1966","unstructured":"Butler, W. T. 1966. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA195:371-375.","journal-title":"JAMA"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1809"},{"key":"e_1_3_2_6_2","first-page":"1229","volume":"34","year":"1996","unstructured":"Domb, A. J., G. Linden, I. Polacheck, and S. Benita. 1996. Nystatin-dextran conjugates: synthesis and characterization. J. Polym. Sci. Part A Polym. Chem.34:1229-1236.","journal-title":"Chem."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(01)00328-5","volume":"74","year":"2001","unstructured":"Duncan, R., S. Gac-Breton, R. Keane, R. Musila, Y. N. Sat, R. Satchi, and F. Searle. 2001. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release74:135-146.","journal-title":"J. Control. Release"},{"key":"e_1_3_2_8_2","first-page":"31","volume":"49","year":"2002","unstructured":"Dupont, B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother.49(Suppl. 1):31-36.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0142-9612(01)00251-4","volume":"23","year":"2002","unstructured":"Ehrenfreund-Kleinman, T., T. Azzam, R. Falk, I. Polacheck, J. Golenser, and A. J. Domb. 2002. Synthesis and characterization of novel water-soluble amphotericin B-arabinogalactan conjugates. Biomaterials23:1327-1335.","journal-title":"Biomaterials"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1975"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2209"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/clinids\/22.1.133","volume":"22","year":"1996","unstructured":"Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis.22(Suppl. 2):133-144.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/bc00030a007","volume":"5","year":"1994","unstructured":"Maeda, M., C. Nishimura, D. Umeno, and M. Takagi. 1994. Psoralen-containing vinyl monomer for conjugation of double-helical DNA with vinyl polymers. Bioconjug. Chem.5:527-531.","journal-title":"Bioconjug. Chem."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinids\/14.Supplement_1.S154","volume":"14","year":"1992","unstructured":"Meyer, R. D. 1992. Current role of therapy with amphotericin B. Clin. Infect. Dis.14(Suppl. 1):154-160.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_15_2","unstructured":"National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A 2nd ed. vol. 22. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/313498"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.9.3606-3609.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.9.3606-3609.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:37:14Z","timestamp":1645468634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.9.3606-3609.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1128\/AAC.48.9.3606-3609.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.9.3606-3609.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"2004-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}